Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced or Metastatic Gastroesophageal Junction Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT07431281
What this trial is testing

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaEsophageal Cancer
AstraZeneca 2,130
Testing effectiveness (Phase 2)Ended earlyNCT02999893
What this trial is testing

APR-246 in Oesophageal Cancer

Who this might be right for
Oesophageal Carcinoma
Peter MacCallum Cancer Centre, Australia 5
Early research (Phase 1)Study completedNCT02572687
What this trial is testing

Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaNon-Small Cell Lung Cancer+1 more
Eli Lilly and Company 85
Testing effectiveness (Phase 2)Study completedNCT03861793
What this trial is testing

A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

Who this might be right for
Advanced Solid Tumors
Mural Oncology, Inc 116
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06241469
What this trial is testing

Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study

Who this might be right for
Gastric CancerGastroEsophageal CancerAdenocarcinoma
Wu Jun 40
Early research (Phase 1)Active Not RecruitingNCT04535401
What this trial is testing

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

Who this might be right for
Advanced Colorectal CarcinomaAdvanced Digestive System CarcinomaAdvanced Gastric Carcinoma+11 more
National Cancer Institute (NCI) 10
Early research (Phase 1)Looking for participantsNCT05365581
What this trial is testing

ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction (GEJ) AdenocarcinomaPancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc. 398
Early research (Phase 1)Enrolling By InvitationNCT07218003
What this trial is testing

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Who this might be right for
Non Small Cell Lung CancerCervical CancerHead and Neck Squamous Cell Cancer+7 more
Rondo Therapeutics 149
Early research (Phase 1)Looking for participantsNCT07705035
What this trial is testing

DBC-664 in Adult Patients With Solid Tumors

Who this might be right for
Malignant Germ Cell TumorLung AdenocarcinomaGastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma+3 more
Duboce Biopharmaceuticals, Inc. 210
Testing effectiveness (Phase 2)Ended earlyNCT01774851
What this trial is testing

MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Who this might be right for
HER-2 Gene AmplificationEsophagus CancerGastroesophageal Junction Cancer+1 more
Merrimack Pharmaceuticals 84
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07692334
What this trial is testing

Becotatugvedotin Plus Pucotenlimab in EGFR-Positive Advanced Gastric/GEJ Adenocarcinoma

Who this might be right for
Gastric CancerGastroesophageal Junction (GEJ) AdenocarcinomaBecotatug Vedotin+1 more
West China Second University Hospital 28
Early research (Phase 1)Active Not RecruitingNCT06781983
What this trial is testing

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced or Metastatic Solid Tumors
Innate Pharma 145
Testing effectiveness (Phase 2)Looking for participantsNCT07488676
What this trial is testing

ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Who this might be right for
Gastric or Gastro-esophageal Junction (GEJ) AdenocarcinomaPancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc. 150
Testing effectiveness (Phase 2)Active Not RecruitingNCT06251973
What this trial is testing

AgenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Who this might be right for
Metastatic Esophageal CarcinomaAdvanced Unresectable Gastric AdenocarcinomaMetastatic Gastric Cancer+10 more
Memorial Sloan Kettering Cancer Center 20
Testing effectiveness (Phase 2)Study completedNCT04989816
What this trial is testing

Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens

Who this might be right for
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
AstraZeneca 95
Large-scale testing (Phase 3)Looking for participantsNCT07673887
What this trial is testing

ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc. 570
Large-scale testing (Phase 3)Study completedNCT03777657
What this trial is testing

Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

Who this might be right for
Gastric, or Gastroesophageal Junction Adenocarcinoma
BeiGene 997
Early research (Phase 1)Study completedNCT03821233
What this trial is testing

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Who this might be right for
HER2-expressing Cancers
Zymeworks BC Inc. 112
Large-scale testing (Phase 3)Active Not RecruitingNCT03653507
What this trial is testing

Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Not applicableLooking for participantsNCT06902545
What this trial is testing

Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Korea, Inc.
Next Page
507
377